Kiniksa Pharmaceuticals International plc-A 2026年季度报告

Kiniksa Pharmaceuticals International, plc(Exact Name of Registrant as Specified in Its Charter) Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filingrequirements for the past 90 days. Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 ofRegulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit suchfiles). Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or anemerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growthcompany” in Rule 12b-2 of the Exchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any newor revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.◻ Indicate by check mark whether the registrant is a shell company (as defined in Rule12b-2 of the Exchange Act). Yes☐No☒As of April 24, 2026, there were 76,938,016 ordinary shares outstanding in aggregate, comprised of:46,303,276 Class A ordinary shares, nominal value $0.000273235 per share1,795,158 Class B ordinary shares, nominal value $0.000273235 per share12,781,964 Class A1 ordinary shares, nominal value $0.000273235 per share16,057,618 Class B1 ordinary shares, nominal value $0.000273235 per share Kiniksa Pharmaceuticals International,plc FORM10-Q FOR THE THREE MONTHS ENDED MARCH 31, 2026 TABLE OF CONTENTS PARTI— FINANCIAL INFORMATIONItem1. Financial Statements (unaudited) 4Condensed Consolidated Balance Sheets as of March 31, 2026 and December 31, 20254Condensed Consolidated Statements of Operations and Comprehensive Income for the threemonths ended March 31, 2026 and 20255Condensed Consolidated Statements of Shareholders’ Equity for the three months ended March31, 2026 and 20256Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2026and 20257Notesto Condensed Consolidated Financial Statements8Item2. Management’s Discussion and Analysis of Financial Condition and Results of Operations23Item3. Quantitative and Qualitative Disclosures About Market Risk31Item4. Controls and Procedures31 PARTII— OTHER INFORMATION Item1. Legal Proceedings33Item1A. Risk Factors33Item2.Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of EquitySecurities33Item3.Defaults Upon Senior Securities33Item4.Mine Safety Disclosures33Item5.Other Information34Item6.Exhibits35 SIGNATURES36 SPECIAL NOTEREGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q (this “Quarterly Report”) contains forward-lookingstatements. All statements other than statements of historical facts contained in this Quarterly Reportshould be considered forward-looking statements, including statements regarding: our beliefs that KPL-387 will expand the recurrent pericarditis market and provide additional treatment options for patients; ourbeliefs about dosing and administration for our product candidates, including that KPL-387 has thepotential for monthly subcutaneous self-administration in a liquid formulation and that KPL-1161 has thepotential for quarterly subcutaneous dosing; our expectation to have data from the Phase 2 portion of ourtrial of KPL-387 in recurrent pericarditis in the second half of 2026 and that we plan to use the totality ofthe data to determine further development strategy; our plan to initiate a Phase 1 first-in-human clinicaltrial of KPL-1161 by the end of 2026; our expectation that our cash balance and our expected cash inflowsfrom operations will allow us to meet our current operating plan and that our existing cash, cashequivalents and short-term investments will enable us to fund our operating expenses and capitalexpenditure requirements for at least the next 12 months; statements regarding our expected near-termexpenditures and revenue; and other similar statements. These statements involve known and unknown risks, uncertainties and other important factorsthat may cause our actual results, performance or achievements to be materially different from any futureresults, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,”“should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “goal,” “design,” “target,” “project,”“contemplate